Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SR121463B

Phase 3Small molecule

SR121463B is one of 11 small molecule programs targeting Hyponatremia. It is currently in Phase 3.

1

Indications

3

Total Trials

0

Active Trials

10

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyponatremiaActive, not recruiting

HyponatremiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Hyponatremia

#DrugCompanyPhaseTrials

Samsca

Jardiance

Boehringer Ingelheim

Vaprisol

CCumberland Pharmaceuticals

Sterile Urea

Lixivaptan

PPalladio Biosciences

Satavaptan

YM087

CCumberland Pharmaceuticals

SR121463B

Conivaptan Hydrochloride

CCumberland Pharmaceuticals

Proamatine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyponatremia1 trial

DILIPO (DILutIonal HyPOnatremia)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00274326·150 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Completed· Sanofi logo

Sanofi·Phase 3·NCT00264927·77 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Completed· Sanofi logo

Sanofi·Phase 3·NCT00264914·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SR121463B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SR121463B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SR121463B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Related News